Fusion Antibodies (LSE:FAB) Change In Receivables : £0.73 Mil (TTM As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Change In Receivables?

Fusion Antibodies's change in receivables for the quarter that ended in Sep. 2023 was £0.22 Mil. It means Fusion Antibodies's Accounts Receivable declined by £0.22 Mil from Mar. 2023 to Sep. 2023 .

Fusion Antibodies's change in receivables for the fiscal year that ended in Mar. 2023 was £0.82 Mil. It means Fusion Antibodies's Accounts Receivable declined by £0.82 Mil from Mar. 2022 to Mar. 2023 .

Fusion Antibodies's Accounts Receivable for the quarter that ended in Sep. 2023 was £0.47 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Fusion Antibodies's Days Sales Outstanding for the six months ended in Sep. 2023 was 158.89.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Fusion Antibodies's liquidation value for the six months ended in Sep. 2023 was £0.50 Mil.

Fusion Antibodies Change In Receivables Historical Data

The historical data trend for Fusion Antibodies's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Change In Receivables Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Receivables

Get a 7-Day Free Trial

-0.16

0.17

-0.55

-0.08

0.82

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Change In Receivables	Get a 7-Day Free Trial											-0.28	0.19	0.30	0.52	0.22

Fusion Antibodies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.73 Mil.

Fusion Antibodies (LSE:FAB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Fusion Antibodies's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.471	/	0.541	*	91
=	158.89

2. In Ben Graham's calculation of liquidation value, Fusion Antibodies's accounts receivable are only considered to be worth 75% of book value:

Fusion Antibodies's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.487	-	0.604	+	0.75 * 0.471	+	0.5 * 0.524
=	0.50

Fusion Antibodies Change In Receivables Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022